Proceedings of the International scientific and practical conference ―Science at the Frontier of Civilizations‖ (March 16-18, 2026) / Publisher website: www.naukainfo.com. – Helsinki, Finland, 2026. - 145 p.

12 use this information to improve clinical management. To achieve this goal, large international registries of patients with MPN, fully characterized by NGS for somatic and germline mutations, are needed, allowing correlation of disease course, complications, and response to therapy with the mutational profiles of patients [6]. The discovery of driver mutations in JAK2, CALR, and MPL has clarified the genetic basis of most MPNs, and the use of high-throughput NGS technologies has further expanded our understanding of these diseases. Identification of non-driver mutations, among other things, allows for improved diagnosis, stratification of risk assessment, optimization of clinical decision-making in patients eligible for hematopoietic cell transplantation (HCT), and monitoring of response to therapy. REFERENCES: 1 Khoury J.D, Solary E., Abla O., Akkari Y., Alaggio R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/ Dendritic Neoplasms. Leukemia (2022) 36:1703– 1719; https://doi.org/10.1038/s41375-022-01613-1 2 Greenfield G., McMullin M.F., and Mills K. Molecular pathogenesis of the myeloproliferative neoplasms J Hematol Oncol https://doi.org/10.1186/s13045-021-01116-z 3 Grinfeld J., Nangalia J., Baxter E. J., Wedge D.C. et al. Disease heterogeneity and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018 October 11; 379(15): 1416–1430. doi:10.1056/NEJMoa1716614 4 Williams N, Lee J, Moore L, Baxter EJ, Hewinson J, Dawson KJ, et al. Phy logenetic reconstruction of myeloproliferative neoplasm reveals very early origins and lifelong evolution. bioRxiv. 2020:2020.11.09.374710. 5 Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631–42.